Ozmosi | Dasatinib Drug Profile

Product Description

Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications including imatinib (Gleevec) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in people who can no longer benefit from other leukemia medications or who cannot take these medications because of side effects. Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607063.html)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dasatinib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Jordan, Korea, Lebanon, Malaysia, Netherlands, New Zealand, Norway, Portugal, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Tunisia, United Kingdom, United States, Vietnam

Active Clinical Trial Count: 25

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
HEM-iSMART B	P2	Not yet recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin	2031-10-01		2024-06-28
SJALL23T	P2	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|T-Cell Peripheral Lymphoma\|T-Cell Leukemia\|Acute Lymphoid Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	2027-12-01	12%	2025-02-04	Patient Enrollment\|Primary Endpoints\|Treatments
SENIOR	P2	Recruiting	Osteoporosis\|Bone Diseases, Metabolic	2025-12-31	50%	2023-10-03	Primary Endpoints\|Start Date\|Treatments
NCT03595917	P1	Recruiting	Acute Myeloid Leukemia\|Acute Lymphoid Leukemia\|Lymphoma, B-Cell\|Blast Crisis\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Lymphoid Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|B-Cell Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Myeloid Leukemia	2025-11-01	23%	2023-11-29	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
IRB-68603	P1	Recruiting	Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2025-08-01	23%	2023-10-11	Primary Endpoints\|Start Date\|Treatments\|Trial Status
2021-001288-26	P2	Active, not recruiting	HIV Infections	2024-07-29
NCI-2012-00037	P2	Completed	Breast Cancer	2024-01-31	61%	2024-07-11	Primary Completion Date\|Primary Endpoints\|Study Completion Date
NCI-2011-00267	P2	Completed	Prostate Cancer	2023-12-07	47%	2023-12-16	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
DASA001	P1	Recruiting	Leukemia, Plasma Cell\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Multiple Myeloma\|Acute Lymphoid Leukemia\|Lymphoma, Non-Hodgkin	2023-11-01	59%	2020-10-28	Primary Endpoints\|Treatments
VHR ALL	P2	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2034-12-31		2025-06-10	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
jRCT2021210060	P3	Active, not recruiting	Chronic Myeloid Leukemia	2029-03-31
SJALL23H	P2	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2028-05-01	12%	2025-01-11
STUDY00022691	P1	Recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2026-12-31	23%	2025-03-07	Primary Completion Date\|Primary Endpoints\|Treatments
NCT03020030	P3	Active, not recruiting	Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia	2026-11-30	38%	2025-01-04
NCI-2021-08486	P2	Recruiting	Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Myeloid Leukemia	2026-10-30	12%	2024-08-28	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
TOT17	P3	Active, not recruiting	Acute Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2026-09-30	27%	2024-11-27	Primary Endpoints\|Treatments
KISS	P2	Active, not recruiting	Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Chronic Myeloid Leukemia	2025-12-31		2022-11-08	Patient Enrollment\|Primary Endpoints\|Treatments\|Trial Status
GIMEMA Study LAL1509	P2	Completed	Acute Lymphoid Leukemia	2024-12-31		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CA180-226	P2	Completed	Chronic Myeloid Leukemia	2024-10-25		2025-05-02	Treatments
XS004-17	P1	Completed	Healthy Volunteers	2023-08-22		2023-11-27	Primary Endpoints\|Treatments
LPI-JOR-LEB-KSA-TUN-2017-01	P2	Completed	Chronic Myeloid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2023-07-22	55%	2023-09-23	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
DasaHIT	P3	Completed	Chronic Myeloid Leukemia	2023-03-31		2025-06-14	Treatments
2016-004106-34	P2	Completed	Chronic Myeloid Leukemia	2023-02-01		2025-06-06	Treatments
CTR20132365	P2	Recruiting	Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Chronic Lymphoid Leukemia\|Chronic Myeloid Leukemia	None		2025-04-29	Patient Enrollment\|Treatments
CTR20131053	P2	Active, not recruiting	Leukemia	None		2025-04-29	Treatments

Recent News Events

Date	Type	Title
06/03/2025	News Article	Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
05/07/2025	News Article	Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments
04/29/2025	News Article	Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
04/24/2025	News Article	Bristol Myers Squibb Reports First Quarter Financial Results for 2025

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Dasatinib

Alternative Names: dasatinib, sprycel, bms-354825, DAZATINIB Clinical Status: Inactive Latest Update: 2025-06-08 Latest Update Note: Clinical Trial Update